このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Destiny Pharma 将来の成長

Future 基準チェック /06

Destiny Pharmaの収益と利益はそれぞれ年間171.4%と15.5%減少すると予測されていますが、EPS は年間13.6% 減少すると予測されています。

主要情報

-15.5%

収益成長率

-13.6%

EPS成長率

Biotechs 収益成長	26.7%
収益成長率	-171.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	26 Apr 2024

今後の成長に関する最新情報

Recent updates

What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

Feb 11

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Nov 30

業績と収益の成長予測

AIM:DEST - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	-8	N/A	N/A	1
12/31/2024	N/A	-6	-6	-5	2
12/31/2023	1	-6	-6	-5	N/A
9/30/2023	1	-6	-5	-5	N/A
6/30/2023	1	-6	-5	-5	N/A
3/31/2023	1	-6	-6	-6	N/A
12/31/2022	0	-7	-6	-6	N/A
9/30/2022	0	-6	-5	-5	N/A
6/30/2022	0	-6	-5	-5	N/A
3/31/2022	0	-6	-5	-5	N/A
12/31/2021	0	-5	-5	-5	N/A
9/30/2021	0	-5	-7	-6	N/A
6/30/2021	0	-5	-9	-6	N/A
3/31/2021	0	-5	-8	-6	N/A
12/31/2020	0	-5	-8	-5	N/A
9/30/2020	0	-5	-6	-5	N/A
6/30/2020	0	-5	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-5	-5	-5	N/A
9/30/2019	0	-5	-5	-5	N/A
6/30/2019	N/A	-5	-6	-6	N/A
3/31/2019	N/A	-5	-5	-5	N/A
12/31/2018	N/A	-5	-5	-5	N/A
9/30/2018	N/A	-5	-4	-4	N/A
6/30/2018	N/A	-4	-3	-3	N/A
3/31/2018	N/A	-4	-3	-3	N/A
12/31/2017	N/A	-3	-2	-2	N/A
9/30/2017	N/A	-2	N/A	-2	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	-1	N/A	-1	N/A
12/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-2	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DEST今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DEST今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: DEST今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DEST来年は収益がないと予測されています。

高い収益成長: DEST来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DESTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Destiny Pharma 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 29% to UK£2.60

Price target increased by 41% to UK£2.82

Price target increased by 41% to UK£2.82

Price target increased by 34% to UK£2.70

Price target increased to UK£2.50

Price target decreased to UK£3.06

Recent updates

Destiny Pharma plc Receives Innovation Passport Designation by the UK MHRA for XF-73 Nasal for the Prevention of Post-Surgical Site Infections

Price target increased by 29% to UK£2.60

Destiny Pharma plc, Annual General Meeting, Jun 12, 2024

Destiny Pharma plc to Report Fiscal Year 2023 Results on Apr 25, 2024

Price target increased by 41% to UK£2.82

Destiny Pharma plc Announces Clinical Development Update Positive Results from XF-73 Dermal Safety Study

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Price target increased by 41% to UK£2.82

New major risk - Share price stability

Destiny Pharma plc Announces the Publication of New Microbiological Data on Xf-73 (Exeporfinium Chloride), Its Leading Antibacterial Drug,In Frontiers in Cellular and Infection Microbiology

Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

Destiny Pharma plc to Report First Half, 2023 Results on Sep 20, 2023

Destiny Pharma plc Appoints Sir Nigel Rudd as New Chairman

Destiny Pharma plc Announces Departure of Nick Rodgers as Chairman

Destiny Pharma plc Confirms Proposed Phase 3 Development Pathway and Identifies New Life Cycle Management Targets for XF-73 Nasal

We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

Destiny Pharma plc Announces CEO Changes

Price target increased by 34% to UK£2.70

Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Destiny Pharma plc Announces Finalisation of its Phase 3 Development Plans for XF-73 Nasal

Less than half of directors are independent

Price target increased to UK£2.50

Destiny Pharma plc Positive update from EMA on NTCD-M3 Phase 3 plans

Destiny Pharma plc to Report First Half, 2022 Results on Sep 08, 2022

Destiny Pharma plc Announces Publication of New Data on NTCD-M3

Destiny Pharma plc Receives Positive Feedback from the U.S. Food and Drug Administration

Destiny Pharma plc Announces Publication of XF-73 Drug Synergy Data

Destiny Pharma plc Starts New Research Programme

Destiny Pharma plc Announces Board Changes

Destiny Pharma plc Announces Landmark NTCD-M3 Data to Be Presented At Anaerobe

Destiny Pharma plc Appoints Yuri Martina as Chief Medical Officer

Price target decreased to UK£3.06

Less than half of directors are independent

Destiny Pharma plc to Report Fiscal Year 2021 Results on Apr 12, 2022

Price target decreased to UK£3.06

Destiny Pharma plc Receives Positive Scientific Advice from the European Medicines Agency

Destiny Pharma plc Announces Positive Results in XF-73 Dermal Safety Study from Ongoing Agreement with US Government's NIAID

Destiny Pharma plc Announces Successful Outcome of Cooperative R&D Agreement with US Department of Veterans Affairs with NTCD-M3

Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Founder recently sold UK£420k worth of stock

Destiny Pharma plc Announces XF-73 Data Abstract to Be Presented At 2021 ECCMID

Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

Destiny Pharma plc to Report Fiscal Year 2020 Results on Apr 14, 2021

Destiny Pharma Announces Agreement with NIAID to Evaluate A Novel XF-73 Formulation in Skin Wound Infection

New 90-day high: UK£1.33

What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

New 90-day high: UK£1.27

Destiny Pharma plc Announces the Appointment of Mark Wilcox to its Scientific Advisory Board

New 90-day high: UK£1.13

Destiny Pharma Appoints Stephanie Bewick as CBO

Destiny Pharma plc Completes Phase 2b Trial of XF-73 Recruitment

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

New 90-day high: UK£0.88

Destiny Pharma plc Announces Clinical Study Patient Recruitment Update

New 90-day high: UK£0.65

Destiny Pharma plc to Report First Half, 2020 Results on Sep 17, 2020

New 90-day high - UK£0.59

New 90-day low - UK£0.31

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘